Cargando…

Therapeutic Development of Levosimendan in Acute and Advanced Heart Failure: A Systematic Review

Levosimendan (LS) has been progressively used for the treatment of patients developing acute as well as chronic or advanced cardiac dysfunction. It has proven to be a better inotropic agent than its counterparts in terms of its ability to increase the cardiac output in an acutely or chronically deco...

Descripción completa

Detalles Bibliográficos
Autores principales: Desai, Heet N, Sangurima, Leslie, Malik, Maujid Masood, Ganatra, Nency, Siby, Rosemary, Kumar, Sanjay, Khan, Sara, Jayaprakasan, Srilakshmi K, Cheriachan, Doju, Mohammed, Lubna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10198665/
https://www.ncbi.nlm.nih.gov/pubmed/37214028
http://dx.doi.org/10.7759/cureus.37844
_version_ 1785044781956595712
author Desai, Heet N
Sangurima, Leslie
Malik, Maujid Masood
Ganatra, Nency
Siby, Rosemary
Kumar, Sanjay
Khan, Sara
Jayaprakasan, Srilakshmi K
Cheriachan, Doju
Mohammed, Lubna
author_facet Desai, Heet N
Sangurima, Leslie
Malik, Maujid Masood
Ganatra, Nency
Siby, Rosemary
Kumar, Sanjay
Khan, Sara
Jayaprakasan, Srilakshmi K
Cheriachan, Doju
Mohammed, Lubna
author_sort Desai, Heet N
collection PubMed
description Levosimendan (LS) has been progressively used for the treatment of patients developing acute as well as chronic or advanced cardiac dysfunction. It has proven to be a better inotropic agent than its counterparts in terms of its ability to increase the cardiac output in an acutely or chronically decompensated heart without an increase in the myocardial oxygen demand. The purpose of this systematic review, which was carried out in accordance with Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) 2020, was to determine the efficacy and advantages of utilizing LS in patients with both acute and chronic heart failure. We collected and reviewed articles, including clinical trials, literature reviews, randomized and non-randomized control trials, case-control and cohort studies, and systematic reviews and meta-analyses published between January 1, 2012, and November 27, 2022. The databases that were used to collect these articles included Pubmed, Pubmed Central, Cochrane Library, and Google Scholar. After applying appropriate filters, a total of 143 reports were identified from these four databases. They were further screened and subjected to quality assessment tools which finally yielded 21 studies that were included in this systematic review. This review provides strong evidence that the pharmacological properties and different mechanisms of action of LS give it an upper hand over other inotropic agents for its successful administration in patients with either acute or advanced cardiac failure, which consists of left as well as right ventricular failure, either individually or in combination.
format Online
Article
Text
id pubmed-10198665
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-101986652023-05-20 Therapeutic Development of Levosimendan in Acute and Advanced Heart Failure: A Systematic Review Desai, Heet N Sangurima, Leslie Malik, Maujid Masood Ganatra, Nency Siby, Rosemary Kumar, Sanjay Khan, Sara Jayaprakasan, Srilakshmi K Cheriachan, Doju Mohammed, Lubna Cureus Cardiology Levosimendan (LS) has been progressively used for the treatment of patients developing acute as well as chronic or advanced cardiac dysfunction. It has proven to be a better inotropic agent than its counterparts in terms of its ability to increase the cardiac output in an acutely or chronically decompensated heart without an increase in the myocardial oxygen demand. The purpose of this systematic review, which was carried out in accordance with Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) 2020, was to determine the efficacy and advantages of utilizing LS in patients with both acute and chronic heart failure. We collected and reviewed articles, including clinical trials, literature reviews, randomized and non-randomized control trials, case-control and cohort studies, and systematic reviews and meta-analyses published between January 1, 2012, and November 27, 2022. The databases that were used to collect these articles included Pubmed, Pubmed Central, Cochrane Library, and Google Scholar. After applying appropriate filters, a total of 143 reports were identified from these four databases. They were further screened and subjected to quality assessment tools which finally yielded 21 studies that were included in this systematic review. This review provides strong evidence that the pharmacological properties and different mechanisms of action of LS give it an upper hand over other inotropic agents for its successful administration in patients with either acute or advanced cardiac failure, which consists of left as well as right ventricular failure, either individually or in combination. Cureus 2023-04-19 /pmc/articles/PMC10198665/ /pubmed/37214028 http://dx.doi.org/10.7759/cureus.37844 Text en Copyright © 2023, Desai et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Cardiology
Desai, Heet N
Sangurima, Leslie
Malik, Maujid Masood
Ganatra, Nency
Siby, Rosemary
Kumar, Sanjay
Khan, Sara
Jayaprakasan, Srilakshmi K
Cheriachan, Doju
Mohammed, Lubna
Therapeutic Development of Levosimendan in Acute and Advanced Heart Failure: A Systematic Review
title Therapeutic Development of Levosimendan in Acute and Advanced Heart Failure: A Systematic Review
title_full Therapeutic Development of Levosimendan in Acute and Advanced Heart Failure: A Systematic Review
title_fullStr Therapeutic Development of Levosimendan in Acute and Advanced Heart Failure: A Systematic Review
title_full_unstemmed Therapeutic Development of Levosimendan in Acute and Advanced Heart Failure: A Systematic Review
title_short Therapeutic Development of Levosimendan in Acute and Advanced Heart Failure: A Systematic Review
title_sort therapeutic development of levosimendan in acute and advanced heart failure: a systematic review
topic Cardiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10198665/
https://www.ncbi.nlm.nih.gov/pubmed/37214028
http://dx.doi.org/10.7759/cureus.37844
work_keys_str_mv AT desaiheetn therapeuticdevelopmentoflevosimendaninacuteandadvancedheartfailureasystematicreview
AT sangurimaleslie therapeuticdevelopmentoflevosimendaninacuteandadvancedheartfailureasystematicreview
AT malikmaujidmasood therapeuticdevelopmentoflevosimendaninacuteandadvancedheartfailureasystematicreview
AT ganatranency therapeuticdevelopmentoflevosimendaninacuteandadvancedheartfailureasystematicreview
AT sibyrosemary therapeuticdevelopmentoflevosimendaninacuteandadvancedheartfailureasystematicreview
AT kumarsanjay therapeuticdevelopmentoflevosimendaninacuteandadvancedheartfailureasystematicreview
AT khansara therapeuticdevelopmentoflevosimendaninacuteandadvancedheartfailureasystematicreview
AT jayaprakasansrilakshmik therapeuticdevelopmentoflevosimendaninacuteandadvancedheartfailureasystematicreview
AT cheriachandoju therapeuticdevelopmentoflevosimendaninacuteandadvancedheartfailureasystematicreview
AT mohammedlubna therapeuticdevelopmentoflevosimendaninacuteandadvancedheartfailureasystematicreview